CD68 and vasculitis: Over time, a spectrum of immunologic changes has been reported as antibody-mediated rejection (AMR), which initially follows humoral rejection due to vasculitis and edema before the emergence of antibodies corresponding to these changes (anti-CD68 molecule [CD68], anti-platelet and endothelial cell adhesion molecule 1 [PECAM1/CD31], and anti-CD4 molecule [CD4]) and seric donor-specific antibodies (DSA) [8,9].